Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 1/20 | 0.49 |
| ▸ | EPAS1 | Q99814 | 2/20 | 0.46 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.46 |
| ▸ | AR | P10275 | 3/20 | 0.41 |
| ▸ | BRAF | P15056 | 2/20 | 0.37 |
| ▸ | P2RX4 | Q99571 | 1/20 | 0.37 |
| ▸ | STK39 | Q9UEW8 | 1/20 | 0.37 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27983650 | 0.89 | EPAS1 (0.51) | EPAS1MRGPRX4ARBRAFP2RX7 | |
| SCHEMBL8941555 | 0.86 | AR (0.47) | RAB9AMRGPRX4AR | |
| SCHEMBL27888403 | 0.82 | EPAS1 (0.45) | EPAS1MRGPRX4ARSTK39P2RX7 | |
| SCHEMBL6228507 | 0.82 | EPAS1 (0.46) | EPAS1MRGPRX4ARP2RX7 | |
| SCHEMBL6230322 | 0.82 | MAPT (0.52) | RAB9AEPAS1MRGPRX4ARP2RX7 | |
| SCHEMBL27947313 | 0.80 | MRGPRX4 (0.64) | RAB9AEPAS1MRGPRX4BRAF | |
| SCHEMBL6230387 | 0.78 | MEN1 (0.57) | RAB9AEPAS1AR | |
| SCHEMBL11498163 | 0.77 | EPAS1 (0.51) | EPAS1MRGPRX4AR | |
| SCHEMBL27533351 | 0.77 | RAB9A (0.53) | RAB9AAR | |
| SCHEMBL27983376 | 0.77 | MRGPRX4 (0.44) | EPAS1MRGPRX4ARSTK39P2RX7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1334086-B1 | PHENOXYPHENYL ALKANE SULFONATES | BAYER HEALTHCARE AG (DE) | 2005-04-06 | — | — | EP | disclosed |
| US-20040214886-A1 | Phenoxyphenyl alkanesulphonates | BAYER AKTIENGESELLSCHAFT (DE) | 2004-10-28 | — | — | US | disclosed |
| US-6756409-B2 | FOR THERAPY AND PROPHYLAXIS OF PAIN AND/OR NEURODEGENERATIVE DISORDERS | BAYER AKTIENGESELLSCHAFT (DE) | 2004-06-29 | — | — | US | disclosed |
| EP-1334086-A1 | PHENOXYPHENYL ALKANE SULFONATES | Bayer Aktiengesellschaft (DE) | 2003-08-13 | — | — | EP | disclosed |
| US-20030022934-A1 | Phenoxyphenyl alkanesulphonates | BAYER AKTIENGESELLSCHAFT (DE) | 2003-01-30 | — | — | US | disclosed |
| WO-2002026702-A1 | PHENOXYPHENYL ALKANE SULFONATES | BAYER AKTIENGESELLSCHAFT (DE) | 2002-04-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030022934-A1 | Phenoxyphenyl alkanesulphonates | SNCA, CLN6, NLN | RAB9A 2935/4885EPAS1 2148/4885MRGPRX4 1773/4885 |
| US-20040214886-A1 | Phenoxyphenyl alkanesulphonates | SNCA, CLN6, NLN | RAB9A 2935/4885EPAS1 2148/4885MRGPRX4 1773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.